The Toronto-Dominion Bank logo TD - The Toronto-Dominion Bank

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 9
HOLD 8
SELL 0
STRONG
SELL
0
| PRICE TARGET: $89.52 DETAILS
HIGH: $91.51
LOW: $87.53
MEDIAN: $89.52
CONSENSUS: $89.52
DOWNSIDE: 19.98%

Stock News

Visible Alpha Breakdown Of Canadian Big Banks' Q2 2026 Earnings Expectations

Visible Alpha Breakdown Of Canadian Big Banks' Q2 2026 Earnings Expectations

Canada's largest banks head into fiscal Q2 2026 earnings facing a more complex macro backdrop than they did just three months ago. Visible Alpha consensus expectations show Canada's major banks are still poised to deliver resilient fiscal Q2 2026 results for the April quarter. Consensus expectations point to healthy year-over-year growth in revenue and earnings across most banks, although profitability metrics such as ROE and NIM are expected to soften sequentially.

May 20, 2026 10:50 PM seekingalpha.com
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the ongoing, real-world IMPACT-TD Registry, highlighting a significant gap in diagnosing tardive dyskinesia (TD) in patients with underlying mood disorders. While the findings demonstrate that most patients across all age groups experience multidimensional impact from the condition, young adults (aged 18-29, n=13) had the lowest rate of formal diagnosis (23%) despite having one of the highest rates of personal impact (85%). The data were presented at the 2026 American Psychiatric Association Annual Meeting, taking place May 16 – 20, 2026 in San Francisco, California.

May 18, 2026 04:00 AM globenewswire.com

Price Targets